Despite promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from managed care entities. Such insurers are https://elijahgzqf122132.jiliblog.com/98425246/copyright-s-vyndamax-faces-is-meeting-pbm-challenges-a-look-at-reimbursement-disputes